AbbVie Inc. (ABBV)
AbbVie would gain an experimental eczema drug by buying biotech: report
AbbVie is reportedly trying to buy a biotech company that is developing a promising atopic dermatitis drug for $10.9 billion in cash, according to a Financial Times report.
AbbVie: Immunology Cash Flow Funds Oncology Expansion
I continue to cover AbbVie with a 'Buy' rating due to its R&D achievements. So, in the past 3 months, Decnupaz and Skinvive by Juvederm have received FDA approvals. Moreover, a week ago, AbbVie reported promising results from the Phase 3 CLL14 trial for the treatment of chronic lymphocytic leukemia patients.
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
In the most recent trading session, AbbVie (ABBV) closed at $216.49, indicating a -2.14% shift from the previous trading day.
3 Dividend Stocks That Pay You More Every Single Year
Income investors keep coming back to the same playbook in choppy markets: own businesses that have raised their payouts every single year, no matter what the economy is doing.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
AbbVie: Maintaining My Strong Buy Rating After Label Expansion
AbbVie maintains strong momentum in immunology, with Skyrizi and Rinvoq offsetting Humira declines and driving double-digit revenue growth. I reaffirm a 'Strong Buy' rating, supported by expanding indications for Skyrizi in Crohn's Disease and Rinvoq in alopecia areata and vitiligo. Skyrizi's subcutaneous induction for Crohn's Disease, validated by phase 3 AFFIRM data, targets further market share and revenue acceleration.
This $15 Billion Operational Beat Just Rewrote the Entire Bear Thesis for AbbVie
For income investors weighing biopharma exposure, the dividend question on AbbVie (NYSE:ABBV | ABBV Price Prediction) just got a lot easier to answer.
AbbVie Stock Will Hit $300 on This Date
AbbVie (NYSE:ABBV | ABBV Price Prediction) has quietly become one of healthcare's most underrated growth stories.
Brokers Suggest Investing in AbbVie (ABBV): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
AbbVie (ABBV) Rises Higher Than Market: Key Facts
AbbVie (ABBV) closed at $227.73 in the latest trading session, marking a +1.32% move from the prior day.
AbbVie: Growth-Pharma Profile At A Value-Pharma Price
AbbVie Inc. is rated a 'Buy' on accelerating fundamentals, robust pipeline progress, and a macro backdrop favoring defensive growth. SKYRIZI and RINVOQ are projected to deliver ~$31.8 billion in FY2026E revenue, with neuroscience emerging as a second growth pillar targeting ~$12.6 billion. EPS is expected to surge ~43% to $14.26 in FY2026E, with FCF up 54% and net debt/EBITDA declining to 1.6x.
Up 45% Since 2024: 1 Glaring Reality That Makes AbbVie Stock a Hold at $225
AbbVie (NYSE:ABBV | ABBV Price Prediction) at $224.95 sits at the center of a sharp bull-bear debate.
